Heart Failure Clinical Trial

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Summary

The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria

- Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability.

Exclusion Criteria

Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant.
Other protocol-defined Inclusion/Exclusion criteria apply.

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

48

Study ID:

NCT06122779

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 35 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35233, United States More Info
Pankaj Arora, Site 0002
Contact
Infinite Clinical Research
Miami Florida, 33133, United States More Info
Sander Fernandez, Site 0003
Contact
Emory Heart and Vascular Center
Atlanta Georgia, 30322, United States More Info
Alanna Morris, Site 0014
Contact
Local Institution - 0048
Atlanta Georgia, 30322, United States
Bluhm Cardiovascular Institute of Northwestern
Chicago Illinois, 60611, United States More Info
Ravi B Patel, Site 0004
Contact
Chicago Medical Research, LLC
Hazel Crest Illinois, 60429, United States More Info
Suhail Khadra, Site 0005
Contact
708-798-8522
Local Institution - 0029
Indianapolis Indiana, 46260, United States More Info
Site 0029
Contact
Local Institution - 0045
Indianapolis Indiana, 46260, United States
St. Louis Heart and Vascular
Saint Louis Missouri, 63136, United States More Info
Harvey Serota, Site 0028
Contact
314-741-0911
Local Institution - 0043
Saint Louis Missouri, 63136, United States
Weill Cornell Medicine
New York New York, 10065, United States More Info
Parag Goyal, Site 0008
Contact
Local Institution - 0041
Oklahoma City Oklahoma, 73135, United States
South Oklahoma Heart Research
Oklahoma City Oklahoma, 73135, United States More Info
Naeem Tahirkheli, Site 0016
Contact
405-628-6865
Tennessee Center for Clinical Trials
Tullahoma Tennessee, 37388, United States More Info
Dinesh Gupta, Site 0001
Contact
931-461-2663
University of Texas Southwestern Medical Center
Dallas Texas, 75390, United States More Info
Ambarish Pandey, Site 0036
Contact
214-645-8000
Angiocardiac Care of Texas - PA - PPDS
Houston Texas, 77025, United States More Info
Amin Karim, Site 0015
Contact
281-944-3610
Local Institution - 0051
Houston Texas, 77025, United States
Medicus MFC Inc.
Toronto Ontario, M4P 1, Canada More Info
Gordon Moe, Site 0037
Contact
4168645319
Local Institution - 0030
Toronto Ontario, M5S 1, Canada More Info
Site 0030
Contact
Local Institution - 0040
Toronto Ontario, M5S 1, Canada
Local Institution - 0035
Trois-Rivieres Quebec, G9A 1, Canada More Info
Site 0035
Contact
Local Institution - 0019
Napoli Campania, 80131, Italy More Info
Site 0019
Contact
Local Institution - 0022
Melegnano Lombardia, 20077, Italy More Info
Site 0022
Contact
Local Institution - 0023
Milano Lombardia, 20162, Italy More Info
Site 0023
Contact
Local Institution - 0033
Milano Lombardia, 20162, Italy
Local Institution - 0050
San Donato Milanese Lombardia, 20097, Italy
Local Institution - 0027
Foggia Puglia, 71100, Italy
Local Institution - 0038
Foggia Puglia, 71100, Italy More Info
Site 0038
Contact
Local Institution - 0052
Massa Toscana, 54100, Italy
Local Institution - 0017
Pisa Toscana, 56124, Italy More Info
Site 0017
Contact
Local Institution - 0009
Bergamo , 24127, Italy More Info
Site 0009
Contact
Local Institution - 0020
Lublin Lubelskie, 20-95, Poland More Info
Site 0020
Contact
Local Institution - 0013
Lódz Lódzkie, 92-21, Poland More Info
Site 0013
Contact
Local Institution - 0031
Bialystok Podlaskie, 15-27, Poland More Info
Site 0031
Contact
Local Institution - 0044
Bialystok Podlaskie, 15-27, Poland
Local Institution - 0006
Krakow , 30-08, Poland
Local Institution - 0049
Lublin , 20-95, Poland
Local Institution - 0024
Oswiecim , 51162, Poland
Hospital Universitario de Bellvitge
Hospitalet de Llobregat Barcelona, 08907, Spain More Info
Josep Comin, Site 0012
Contact
34932483123
Hospital Universitario Puerta de Hierro - Majadahonda
Majadahonda Madrid, 28222, Spain More Info
Pablo García Pavia, Site 0025
Contact
+34911917297
Local Institution - 0047
Majadahonda Madrid, 28222, Spain
Hospital Universitario Virgen de La Arrixaca
El Palmar Murcia, 30120, Spain More Info
Domingo Pascual-Figal, Site 0021
Contact
+34968369662
Local Institution - 0039
El Palmar Murcia, 30120, Spain
Hospital Universitario Virgen de la Victoria
Malaga Málaga, 29010, Spain More Info
José Manuel García Pinilla, Site 0032
Contact
+34951032349
Local Institution - 0042
Malaga Málaga, 29010, Spain
Hospital Universitario Ramon y Cajal
Madrid , 28034, Spain More Info
Pau Llacer Iborra, Site 0026
Contact
34913368923
Local Institution - 0034
Madrid , 28034, Spain
Hospital Nuestra Señora de Valme
Sevilla , 41014, Spain More Info
Antonio Reyes Dominguez, Site 0018
Contact
34955015777
Local Institution - 0046
Sevilla , 41014, Spain
Hospital Clinico Universitario de Valencia
Valencia , 46010, Spain More Info
Julio Nuñez Villota, Site 0010
Contact
+34961973520

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

48

Study ID:

NCT06122779

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.